1. 肿瘤瞭望：感谢您参加我们的会议，请您简单做下自我介绍。

Hong Jae Chon教授：我叫Hong Jae Chon，是来自韩国CHA盆唐医疗中心的一名肿瘤内科医生，专业研究领域是肝癌的系统治疗，当然免疫治疗是目前主要的治疗方法。很高兴来到这里参会，感谢组委会和大会主席陆教授的邀请。

Oncology Frontier: Thank you for attending our meeting and I'm going to ask you to introduce yourself to our audience.

Hong Jae Chon: Nice to meet you. I am Hong Jae Chon from CHA Bundang Medical Center in South Korea. I am a medical oncologist, specializing in liver cancer. I treat patients with systemic therapy, and nowadays, immunotherapy is the main treatment. I am very glad to be here, and thank you to the Organizing Committee and Professor Lu. Thank you.

2. 肿瘤瞭望：请问您参加这次CCHIO大会感受如何？

Hong Jae Chon教授：这次会议给我留下了深刻的印象，肿瘤内科医生、肝病学家和外科医生齐聚一堂，分享我们的想法，并就最近的研究数据发表演讲。学习不同外科医生、肝病学家和不同研究人员的其他想法对我很有帮助。

Oncology Frontier: How do you feel about attending the CCHIO conference？

Hong Jae Chon: I am very impressed by this Conference, with medical oncologists, hepatologists and surgeons all getting together to share our ideas and make presentations about the recent dates. It is very helpful for me to hear other ideas from different surgeons,hepatologists and different researchers.

3. 肿瘤瞭望：免疫治疗已成为晚期肝癌患者的主要治疗方法，您能否介绍一下免疫治疗HCC相关的最新研究进展？

Hong Jae Chon教授：阿替利珠单抗/贝伐珠单抗联合治疗已成为晚期肝癌的标准治疗，全身免疫治疗是该人群的主要治疗方法。最近，更多的联合疗法，如TPST-1120联合阿替利珠单抗/贝伐珠单抗作为三联疗法显示出非常有前景的研究数据，正在进入III期临床研究。我预计更多的HCC患者可以从未来更好的免疫治疗组合中获得临床获益。

Oncology Frontier: Immunotherapy has become an main treatment for patients with advanced liver cancer, can you introduce the latest research progress related to immunotherapy in HCC?

Hong Jae Chon: Atezolizumab/bevacizumab combination therapy has become standard-of-care. Systemic immunotherapy is the mainstay of treatment in this population. Recently, more combination therapies, such as TPST-1120 combined with atezolizumab/bevacizumab as a triple combination has shown very promising research data. This is moving to a phase III clinical study. I expect more HCC patients can get clinical benefit from future and better combinations of immunotherapy.

4. 肿瘤瞭望：选择免疫治疗的候选药物对于改善肝癌患者的预后至关重要，您认为哪些分子标志物可以预测免疫治疗对肝癌的反应？

Hong Jae Chon教授：到目前为止，我们还没有明确的癌症免疫治疗生物标志物，但也许我们可以从之前的肝脏研究中获得一些信息。例如，在我今天的演讲中，高血清 IL-6 对阿替利珠单抗/贝伐珠单抗治疗的反应不佳，而肿瘤细胞Treg高表达的患者对检查点抑制反应不佳。我们必须尝试更多不同的联合疗法来克服这些局限性。

Oncology Frontier: Choosing the candidate for immunotherapy is critical to improving outcomes in liver cancer patients, what molecular markers do you think can predict the response of immunotherapy in HCC?

Hong Jae Chon: Up until now, we have had no definitive biomarkers for cancer immunotherapy, but maybe we can get some signals from our prior liver studies. For example, in my presentation today, high serum IL-6 didn’t show as good a response to atezolizumab/bevacizumab treatment and those patients with high levels of Treg in their tumor didn’t show a good response to checkpoint inhibition. We have to trial more different combination therapies to overcome these limitations.